MedTrace Logo

Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?

NCT04319328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-05-16

No results posted yet for this study

Summary

This study aims to optimize the dosing of cefazolin, ceftazidime, and ciprofloxacin for patients on high-flux hemodialysis. For each antibiotic 20 participants will be enrolled and three blood samples will be collected from each participant. Antibiotic levels will be measured in each blood sample. This data will be used to develop population-pharmacokinetic models for each antibiotic. Finally, Monte Carlo simulations will be used to develop evidence-based dosing recommendations.

Conditions

Interventions

DRUG

Cefazolin

Non-interventional pharmacokinetic evaluation

DRUG

Ceftazidime

Non-interventional pharmacokinetic evaluation

Sponsors & Collaborators

  • The Kidney Foundation of Canada

    collaborator OTHER

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Sheryl A Zelenitsky, PharmD · University of Manitoba

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-18
Primary Completion
2024-04-30
Completion
2024-04-30
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04319328 on ClinicalTrials.gov